Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the random-ised, placebo-controlled, phase 3 trial (vol 19, pg 998, 2020)

被引:0
作者
Wolinsky, J. S.
Arnold, D. L.
Brochet, B.
机构
关键词
D O I
10.1016/S1474-4422(20)30437-3
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
引用
收藏
页码:E1 / E1
页数:1
相关论文
共 1 条
[1]   Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial [J].
Wolinsky, Jerry S. ;
Arnold, Douglas L. ;
Brochet, Bruno ;
Hartung, Hans-Peter ;
Montalban, Xavier ;
Naismith, Robert T. ;
Manfrini, Marianna ;
Overell, James ;
Koendgen, Harold ;
Sauter, Annette ;
Bennett, Iain ;
Hubeaux, Stanislas ;
Kappos, Ludwig ;
Hauser, Stephen L. .
LANCET NEUROLOGY, 2020, 19 (12) :998-1009